Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 TANGHong-mei ¹ ,  TUXing ^1,2 , XIONGFen ¹ , LUOQian ¹ , SUFen-li ¹ , SUZhi-qiang ¹ , ZHANGQing-ye ¹ , CAIQing-qun ¹

1. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;
2. Guangzhou University of Chinese Medicine, Guangzhou 510405, China;

Corresponding author：

TUXing, Email: kuangsheng1234@126.com

Keywords：

Cisplatin; EP regimen; Small cell lung cancer; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.20150075

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of cisplatin combined with etoposide versus other platinum combined with etoposide in the treatment of small cell lung cancer (SCLC). Methods We searched PubMed, The Cochrane Library (Issue 8, 2013), MEDLINE (Ovid), CNKI, VIP and WanFang Data to collect randomized controlled trials (RCTs) concerning the efficacy and safety of cisplatin combined with etoposide (the cisplatin group) versus other platinum combined with etoposide (the control group) for SCLC. The search was up to August 2013. Two reviewers screened literatures according to the inclusion and exclusion criteria, extracted data and assessed the methodological quality of included studies. And then, meta-analysis was performed by using RevMan 5.2 software. Results A total of 6 RCTs involving 684 patients were included. The results of meta-analysis showed that there were no significant differences in disease control rate (DCR) (RR=1.03, 95%CI 0.91 to 1.17, P=0.63), overall response rate (ORR) (RR=1.04, 95%CI 0.97 to 1.11, P=0.33), occurrence of leukocytopenia (RR=0.97, 95%CI 0.81 to 1.17, P=0.77), decreased hemoglobin (RR=0.89, 95%CI 0.61 to 1.31, P=0.56) between the cisplatin group and the control group. Occurrence of thrombocytopenia was lower (RR=0.49, 95%CI 0.38 to 0.63, P<0.000 01) while occurrence of nausea and vomiting was higher (RR=1.80, 95%CI 1.40 to 2.31, P<0.000 01) in the cisplatin group. Conclusion Current evidence shows that the clinical efficacy of cisplatin combined with etoposide for SCLC is equal to other platinum combined with etoposide, but it has a certain advantage in decreasing the aggregative rate of platelets, while the gastrointesnial reaction patients should avoid using cisplatin combined with etoposide.

Citation： TANGHong-mei, TUXing, XIONGFen, LUOQian, SUFen-li, SUZhi-qiang, ZHANGQing-ye, CAIQing-qun. Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2015, 15(4): 452-457. doi: 10.7507/1672-2531.20150075 Copy

1.	胡义德, 钱桂生. 小细胞肺癌综合治疗:实践指南. 中华肺部疾病杂志(电子版), 2011, 4(5):356-359.
2.	曹子昂. 2014第一版NCCN小细胞肺癌治疗指南解读. 中国前沿医学杂志(电子版), 2013, 5(12):79-81.
3.	张笑辰, 张丽锦, 邹蕴, 等. 顺铂及顺铂载体的研究进展. 中国当代医药, 2011, 18(22):25-26.
4.	唐棣华. 抗癌药物顺铂抗癌机制的线索. 化学研究与应用, 2010, (1):96.
5.	Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer (AJCC) cancer staging manual. 7^th ed. Chicago:Spring, Inc, 2009:103-115.
6.	邓可刚. 循证医学证据的检索步骤与检索系统的选择. 中国循证医学杂志, 2004, 4(9):634-637.
7.	罗杰, 冷卫东. 系统评价/Meta分析理论与实践. 北京:军事医学科学出版社, 2013:76.
8.	李然, 王睿, 汤建华, 等. 紫杉醇治疗小细胞肺癌的系统评价. 中国循证医学杂志, 2008, 8(10):851-860.
9.	Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase Ⅲ trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer:JCGO 9702. Br J Cancer, 2007, 97(2):162-169.
10.	齐晓倩, 魏长宏, 武贵存, 等. 洛铂、顺铂分别联合足叶乙苷治疗老年小细胞肺癌对照研究. 武警后勤学院学报, 2012, 21(4):258-262.
11.	于清清, 王明玉. 洛铂或顺铂联合依托泊苷治疗初治小细胞肺癌临床疗效的观察. 肿瘤药, 2013, 3(2):107-110.
12.	Guo W, Liao G, Gao H, et al. Randomized comparison of lobaplatin plus etoposide and cisplatin plus etoposide chemotherapy in patients with extensive-stage small cell lung cancer. Chinese-German J Clin Oncol, 2013, 12(8):365-368.
13.	Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treated withcisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, 2013, 38(1):51-54.
14.	陈天君, 高飞, 孙忠民, 等. 依托泊苷联合洛铂或顺铂治疗广泛期小细胞肺癌的对照研究. 西安交通大学学报(医学版), 2013, 24(2):198-201.
15.	Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol, 2003, 30(1):9-25.
16.	赵艳萌, 高丽萍, 郭卓雨. 顺铂诱发肾毒性机制的研究进展. 广东医学, 2013, 34(23):3679-3681.
17.	郑日葵. 顺铂同步放疗在肺癌治疗中的毒性分析和剂量控制. 海峡药学, 2013, 25(2):66-67.
18.	于大连, 亓卫东, 张梅, 等. 顺铂及其耳毒性. 中国耳科学杂志, 2008, 6(2):125-133.
19.	王金全, 姚林. 顺铂所致的周围神经毒性及其防治措施. 中国新药杂志, 2005, 14(10):1236-1239.
20.	闫长会, 施畅, 李玉凤, 等. 新铂类药物双环铂与顺铂、卡铂体内毒性的比较研究. 中国新药杂志, 2005, 14(10):1156-1159.
21.	邓建浩, 史道华. 铂类药物神经毒性的药物基因组学研究进展. 中国临床药理学与治疗学, 2012, 17(4):458-462.

1. 胡义德, 钱桂生. 小细胞肺癌综合治疗:实践指南. 中华肺部疾病杂志(电子版), 2011, 4(5):356-359.
2. 曹子昂. 2014第一版NCCN小细胞肺癌治疗指南解读. 中国前沿医学杂志(电子版), 2013, 5(12):79-81.
3. 张笑辰, 张丽锦, 邹蕴, 等. 顺铂及顺铂载体的研究进展. 中国当代医药, 2011, 18(22):25-26.
4. 唐棣华. 抗癌药物顺铂抗癌机制的线索. 化学研究与应用, 2010, (1):96.
5. Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer (AJCC) cancer staging manual. 7^th ed. Chicago:Spring, Inc, 2009:103-115.
6. 邓可刚. 循证医学证据的检索步骤与检索系统的选择. 中国循证医学杂志, 2004, 4(9):634-637.
7. 罗杰, 冷卫东. 系统评价/Meta分析理论与实践. 北京:军事医学科学出版社, 2013:76.
8. 李然, 王睿, 汤建华, 等. 紫杉醇治疗小细胞肺癌的系统评价. 中国循证医学杂志, 2008, 8(10):851-860.
9. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase Ⅲ trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer:JCGO 9702. Br J Cancer, 2007, 97(2):162-169.
10. 齐晓倩, 魏长宏, 武贵存, 等. 洛铂、顺铂分别联合足叶乙苷治疗老年小细胞肺癌对照研究. 武警后勤学院学报, 2012, 21(4):258-262.
11. 于清清, 王明玉. 洛铂或顺铂联合依托泊苷治疗初治小细胞肺癌临床疗效的观察. 肿瘤药, 2013, 3(2):107-110.
12. Guo W, Liao G, Gao H, et al. Randomized comparison of lobaplatin plus etoposide and cisplatin plus etoposide chemotherapy in patients with extensive-stage small cell lung cancer. Chinese-German J Clin Oncol, 2013, 12(8):365-368.
13. Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treated withcisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, 2013, 38(1):51-54.
14. 陈天君, 高飞, 孙忠民, 等. 依托泊苷联合洛铂或顺铂治疗广泛期小细胞肺癌的对照研究. 西安交通大学学报(医学版), 2013, 24(2):198-201.
15. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol, 2003, 30(1):9-25.
16. 赵艳萌, 高丽萍, 郭卓雨. 顺铂诱发肾毒性机制的研究进展. 广东医学, 2013, 34(23):3679-3681.
17. 郑日葵. 顺铂同步放疗在肺癌治疗中的毒性分析和剂量控制. 海峡药学, 2013, 25(2):66-67.
18. 于大连, 亓卫东, 张梅, 等. 顺铂及其耳毒性. 中国耳科学杂志, 2008, 6(2):125-133.
19. 王金全, 姚林. 顺铂所致的周围神经毒性及其防治措施. 中国新药杂志, 2005, 14(10):1236-1239.
20. 闫长会, 施畅, 李玉凤, 等. 新铂类药物双环铂与顺铂、卡铂体内毒性的比较研究. 中国新药杂志, 2005, 14(10):1156-1159.
21. 邓建浩, 史道华. 铂类药物神经毒性的药物基因组学研究进展. 中国临床药理学与治疗学, 2012, 17(4):458-462.

Chinese Journal of Evidence-Based Medicine

Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content